View Categories

Stable Angina (Chronic Coronary Syndrome)

21 min read

Background #

Stable angina, now more commonly referred to as Chronic Coronary Syndrome (CCS) in contemporary guidelines, is a clinical condition characterized by predictable chest pain or discomfort due to transient myocardial ischemia that is typically relieved by rest or nitroglycerin. It occurs due to fixed atherosclerotic narrowing of the coronary arteries (typically ≥70% stenosis) that reduces blood flow during increased myocardial oxygen demand.[1,2]

Classification/Types

Clinical Presentations of CCS [1,2]

  1. Chronic stable angina: Predictable chest discomfort with exertion or stress, stable for weeks to months
  2. Silent ischemia: Myocardial ischemia without anginal symptoms (common in diabetics)
  3. Vasospastic (Prinzmetal) angina: Transient coronary artery vasospasm, typically at rest (often early morning), not effort-induced
  4. Microvascular angina: Chest pain with normal epicardial coronary arteries but abnormal coronary microvascular function

Characterization of Chest Pain

Typical Angina (Definite) – Meets all three criteria:

  1. Substernal chest discomfort (pressure, squeezing, heaviness)
  2. Provoked by exertion or emotional stress
  3. Relieved by rest or nitroglycerin (within 5 minutes)

Atypical Angina (Probable): Meets two of the above criteria

Non-anginal Chest Pain: Meets only one or none of the above criteria

Epidemiology

Prevalence

The prevalence of chronic coronary disease (stable angina) in the United States:

  • Approximately 9.2% of adults aged ≥20 years have coronary artery disease based on NHANES data [3]
  • Prevalence increases with age, ranging from 3.2% in ages 40-59 years to 19.8% in ages ≥60 years [3]
  • An estimated 20.1 million adults aged ≥20 years have coronary artery disease in the United States [4]
Demographics

Socioeconomic Status: Low socioeconomic status linked to higher risk due to poor access to preventive care and higher risk factor burden [1]

Sex: More common in men before age 55; incidence equalizes after menopause in women. Women tend to present with atypical symptoms more frequently than men. [1,2]

Age: Usually presents in patients >45 years in men and >55 years in women (post-menopausal) [1]

Race/Ethnicity: Higher prevalence in South Asians and populations in industrialized countries. Non-Hispanic whites have higher prevalence (10.0%) compared to non-Hispanic Blacks (8.0%) and Hispanics (7.4%) [11]

Pathophysiology

Stable angina results from an imbalance between myocardial oxygen supply and demand: [1,2]

Oxygen Supply Reduction
  • Fixed atherosclerotic stenosis (typically ≥70%) limits coronary blood flow reserve
  • During increased demand (exercise, stress), coronary flow cannot increase adequately
  • Stenosis →↓ distal coronary perfusion pressure → subendocardial ischemia
Increased Oxygen Demand
  • Physical exertion → increased heart rate, contractility, and blood pressure
  • Emotional stress → catecholamine release → increased myocardial work
  • Other triggers: cold exposure, heavy meals (postprandial angina)
Ischemic Cascade
  1. Metabolic changes: ATP depletion, lactate accumulation
  2. Diastolic dysfunction: Impaired relaxation (detectable on echo)
  3. Systolic dysfunction: Regional wall motion abnormalities
  4. ECG changes: ST-segment depression, T-wave inversion
  5. Anginal symptoms: Chest discomfort (final manifestation)
Plaque Characteristics
  • Stable plaque: Thick fibrous cap, small lipid core, less inflammation
  • Unlike acute coronary syndrome, stable angina involves chronic, stable atherosclerotic lesions without acute rupture or thrombosis

Etiology #

Primary Cause

Atherosclerotic coronary artery disease (CAD): Most common cause (~90%)

  • Progressive lipid accumulation, inflammation, and fibrosis
  • Results in fixed luminal narrowing

Other Causes

  • Coronary artery vasospasm: Prinzmetal angina (rare)
  • Coronary microvascular dysfunction: Syndrome X
  • Coronary anomalies: Anomalous origin of coronary arteries
  • Coronary artery bridging: Myocardial bridging compressing artery during systole
  • Severe aortic stenosis: Increased LV pressure → subendocardial ischemia
  • Hypertrophic cardiomyopathy: Increased oxygen demand, reduced supply

Risk Factors

Modifiable:

  • Hypertension
  • Diabetes mellitus
  • Dyslipidemia (elevated LDL-C, low HDL-C)
  • Smoking (most potent modifiable risk factor)
  • Obesity (especially central adiposity)
  • Sedentary lifestyle
  • Psychosocial stress
  • Unhealthy diet

Non-modifiable:

  • Male sex
  • Advanced age (men >45 years, women >55 years)
  • Family history of premature CAD (first-degree relatives: men <55 years, women <65 years)
  • Genetic predisposition

Other:

  • Chronic kidney disease (CKD)
  • Inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus)
  • Obstructive sleep apnea
  • Elevated lipoprotein(a)

Clinical Presentation #

History (Symptoms)

Characteristic Features:

  • Nature: Pressure-like, squeezing, tightness, heaviness, or “elephant sitting on chest” (NOT sharp, stabbing, or pleuritic)
  • Location: Substernal or left chest; may radiate to left arm, neck, jaw, back, or epigastrium
  • Duration: Typically 2–10 minutes (usually <20 minutes)
  • Triggers:
    • Physical exertion (walking uphill, climbing stairs)
    • Emotional stress
    • Heavy meals
    • Cold exposure
    • Sexual activity
  • Relief: Rest (within 5 minutes) or sublingual nitroglycerin (within 1-5 minutes)
  • Pattern: Reproducible with similar levels of activity; stable and unchanged over weeks to months

Associated Symptoms:

  • Dyspnea on exertion
  • Fatigue or weakness
  • Diaphoresis
  • Nausea
  • Lightheadedness

Anginal Equivalents (especially in elderly, diabetics, women):

  • Isolated dyspnea on exertion
  • Excessive fatigue
  • Epigastric discomfort

Red Flags Suggesting Unstable Angina (require urgent evaluation):

  • Crescendo pattern (increasing frequency, severity, or duration)
  • Rest angina or angina lasting >20 minutes
  • New-onset angina (<2 months)
  • Post-infarction angina

Physical Examination

Vital Signs:

  • Often normal between episodes
  • May reveal hypertension or tachycardia during anginal episode
  • Assess for hemodynamic stability

Focused Physical Examination

Cardiovascular:

  • Normal heart sounds in most patients with stable angina
  • S4 gallop: Left ventricular hypertrophy (LVH) due to chronic hypertension
  • Murmurs:
    • Aortic stenosis (crescendo-decrescendo systolic murmur) → angina in elderly
    • Mitral regurgitation (holosystolic murmur) → may indicate prior MI with papillary muscle dysfunction
  • Irregular rhythm: Atrial fibrillation or frequent premature ventricular contractions (PVCs)
  • Jugular venous distension (JVD): Suggests heart failure

Pulmonary:

  • Usually clear
  • Bibasilar crackles: Suggest congestive heart failure or pulmonary edema

Peripheral Vascular:

  • Diminished pulses: Peripheral arterial disease (PAD) – suggests systemic atherosclerosis
  • Carotid bruits: Carotid artery stenosis
  • Cool extremities: Decreased peripheral perfusion
  • Edema: Lower extremity edema suggests volume overload or heart failure
  • Cyanosis: Severe hypoxemia or poor perfusion

Abdominal:

  • Palpate for abdominal aortic aneurysm (pulsatile mass)
  • Auscultate for abdominal bruits (renal artery stenosis)

Skin:

  • Xanthomas or xanthelasma: Lipid deposits suggesting familial dyslipidemia
  • Nicotine staining: Smoking history

Other:

  • BMI and waist circumference: Assess for obesity
  • Signs of diabetes: Acanthosis nigricans, diabetic dermopathy

Differential Diagnosis #

Cardiac Causes

  • Acute coronary syndrome (unstable angina, NSTEMI, STEMI) – Most important to rule out
  • Pericarditis: Sharp, pleuritic pain, positional relief (leaning forward), pericardial friction rub
  • Aortic dissection: Tearing pain radiating to back, pulse deficits, blood pressure differential
  • Aortic stenosis: Exertional angina, syncope, heart failure (classic triad)
  • Hypertrophic cardiomyopathy: Exertional angina and dyspnea

Pulmonary Causes

  • Pulmonary embolism: Sudden dyspnea, pleuritic chest pain, tachycardia, hemoptysis
  • Pneumothorax: Sudden onset, unilateral decreased breath sounds, hyperresonance
  • Pneumonia: Fever, productive cough, focal consolidation
  • Pleuritis: Sharp, localized, pleuritic pain

Gastrointestinal Causes

  • Gastroesophageal reflux disease (GERD): Burning sensation, worse after meals or when lying flat
  • Esophageal spasm: Mimics angina, may respond to nitroglycerin (confounding factor)
  • Peptic ulcer disease: Epigastric pain, relieved by antacids
  • Cholecystitis: Right upper quadrant pain, postprandial, Murphy’s sign

Musculoskeletal Causes

  • Costochondritis: Reproducible chest wall tenderness, pain with palpation
  • Muscle strain: Focal pain, history of trauma or overuse
  • Fibromyalgia: Multiple tender points

Psychological

  • Panic attack/anxiety disorder: Associated with hyperventilation, palpitations, sense of doom

Diagnostic Testing #

Initial Tests

Resting 12-Lead Electrocardiogram (ECG)
  • Usually normal in stable angina between episodes
  • May show:
    • Old Q waves: Prior myocardial infarction
    • Left ventricular hypertrophy (LVH): Chronic hypertension
    • ST-T wave abnormalities: Non-specific changes
    • T-wave inversions: Suggest ischemia or prior infarction
  • During anginal episode: May show transient ST-segment depression or T-wave inversions (resolves with rest)
Cardiac Biomarkers
  • Troponin I/T and CK-MB: Should be NORMAL in stable angina
  • If elevated → suggests acute coronary syndrome (NSTEMI)

Additional Tests

  • Complete Blood Count (CBC): Rule out anemia (decreases oxygen delivery)
  • Comprehensive Metabolic Panel (CMP): Assess renal function (guide medication dosing), electrolytes
  • Fasting lipid panel: LDL-C, HDL-C, triglycerides (risk assessment and treatment targets)
  • HbA1c: Screen for diabetes mellitus
  • Thyroid-Stimulating Hormone (TSH): Rule out hyperthyroidism (increases oxygen demand) or hypothyroidism
  • High-sensitivity C-reactive protein (hsCRP): Assess inflammatory risk (optional)

Non-Invasive Stress Testing

Purpose: Detect inducible ischemia, risk stratification, guide management decisions

Exercise Electrocardiography (Exercise Stress Test – EST) [2,5]
  • First-line test for patients who can exercise and have interpretable baseline ECG
  • Indications: Intermediate pretest probability of CAD, diagnostic uncertainty
  • Positive test: ≥1 mm ST-segment depression in ≥2 contiguous leads during or after exercise
  • Duke Treadmill Score: Predicts prognosis and guides management
  • Contraindications:
    • Inability to exercise
    • Baseline ECG abnormalities (LBBB, paced rhythm, ST-segment abnormalities)
    • Acute MI within 2 days
    • Unstable angina
Stress Echocardiography [2,3]
  • Indications:
    • Unable to exercise (use pharmacologic stress: dobutamine)
    • Uninterpretable baseline ECG (LBBB, paced rhythm, resting ST abnormalities)
    • Equivocal exercise ECG results
  • Detects: Regional wall motion abnormalities during stress (indicates ischemia)
  • Advantages: No radiation, assesses LV function
  • Pharmacologic agents: Dobutamine (increases contractility) or vasodilators (adenosine, regadenoson)
Myocardial Perfusion Imaging (Nuclear Stress Test) [2,5]
  • SPECT (Single-Photon Emission Computed Tomography): Technetium-99m or thallium-201
  • PET (Positron Emission Tomography): Rubidium-82 or nitrogen-13 ammonia
  • Indications: Same as stress echo; provides better sensitivity and specificity than exercise ECG alone
  • Detects: Reversible perfusion defects (ischemia) vs. fixed defects (prior infarction)
  • Disadvantages: Radiation exposure, higher cost
Cardiac CT Angiography (CCTA) [2,5]
  • Non-invasive anatomic imaging of coronary arteries
  • High negative predictive value (>95%): Excellent for ruling out significant CAD
  • Indications:
    • Low-to-intermediate pretest probability of CAD
    • Unable to exercise or complete stress test
    • Equivocal stress test results
  • Advantages: Visualizes coronary anatomy, calcification (calcium score)
  • Disadvantages: Radiation, contrast exposure, less useful with heavy calcification
  • Gold standard for assessing myocardial viability and perfusion
  • Indications: Equivocal results from other tests, assessment of myocardial viability
  • Advantages: No radiation, excellent image quality
  • Disadvantages: Expensive, limited availability, contraindicated with certain implanted devices
Stress Cardiac MRI (CMR)[2,5]

Invasive Testing

Coronary Angiography (Cardiac Catheterization) [1,2]
  • Gold standard for definitive diagnosis of CAD
  • Indications:
    • High-risk features on non-invasive testing
    • Refractory angina despite optimal medical therapy
    • Consideration for revascularization (PCI or CABG)
    • Survivors of sudden cardiac arrest
    • Occupational requirements (pilots, etc.)
  • Procedure: Invasive; assesses location, extent, and severity of coronary stenosis
  • Complications: Bleeding, contrast-induced nephropathy, stroke, MI, death (<1%)
Fractional Flow Reserve (FFR) and Instantaneous Wave-Free Ratio (iFR) [2]
  • Invasive physiologic assessment of lesion-specific ischemia during angiography
  • Indication: Intermediate stenoses (40-70%) where significance is uncertain
  • FFR <0.80 or iFR <0.89: Hemodynamically significant stenosis; benefits from revascularization
  • Advantages: Guides decision for PCI in intermediate lesions, improves outcomes

Treatment #

The management of stable angina (chronic coronary syndrome) is based on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with Chronic Coronary Disease. [2] Treatment aims to relieve symptoms and prevent cardiovascular events.

Lifestyle Modifications (Class 1 Recommendation) [2,4]

Cornerstone of therapy – all patients should receive counseling:

  • Smoking cessation: Most important modifiable risk factor; reduces cardiovascular events by 30-50%
    • Offer pharmacotherapy: varenicline, bupropion, nicotine replacement therapy
    • Referral to smoking cessation programs
  • Physical activity:
    • Moderate-intensity aerobic exercise: 150 minutes/week (e.g., brisk walking) OR vigorous-intensity: 75 minutes/week
    • Resistance training: 2 days/week
    • Cardiac rehabilitation for patients post-revascularization or with high-risk features
  • Diet:
    • Mediterranean diet or DASH diet (Class 1) [2,6]
    • Emphasize: vegetables, fruits, whole grains, legumes, nuts, fish, olive oil
    • Limit: saturated fats (<6% of calories), trans fats (eliminate), sodium (<2,300 mg/day), refined sugars, red meat
  • Weight management:
    • Target BMI: 18.5-24.9 kg/m²
    • Waist circumference: <40 inches (men), <35 inches (women)
    • Weight loss of 5-10% reduces cardiovascular risk
  • Alcohol consumption:
    • If consumed: ≤1 drink/day (women), ≤2 drinks/day (men)
    • Avoid if history of alcohol abuse

Anti-Anginal Medications (Symptom Relief)

Nitrates [1,2]

Short-Acting (Immediate Relief):

  • Sublingual nitroglycerin (NTG): 0.4 mg every 5 minutes (up to 3 doses)
    • Use at onset of angina or prophylactically before anticipated exertion
    • If chest pain persists after 3 doses (15 minutes) → seek emergency care (rule out ACS)
    • Side effects: Headache, hypotension, flushing

Long-Acting (Prevention):

  • Isosorbide mononitrate: 30-60 mg once daily (extended-release) or 20 mg twice daily (immediate-release with nitrate-free interval)
  • Isosorbide dinitrate: 20-40 mg three times daily
  • Transdermal nitroglycerin patches: 0.2-0.8 mg/hr (remove at night for 10-12 hour nitrate-free interval to prevent tolerance)

Important:

  • Ensure 8-12 hour nitrate-free interval daily to prevent tolerance
  • Contraindicated: Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension
Beta-Blockers (First-Line) [1,2]

Mechanism: ↓ heart rate, ↓ contractility, ↓ blood pressure → ↓ myocardial oxygen demand

Preferred agents:

  • Metoprolol succinate (extended-release): 25-200 mg once daily
  • Carvedilol: 3.125-25 mg twice daily (also has alpha-blocking properties)
  • Bisoprolol: 2.5-10 mg once daily
  • Atenolol: 25-100 mg once daily (less preferred due to lack of mortality benefit in some studies)

Target: Resting heart rate 55-60 bpm

Contraindications/Cautions:

  • Severe bradycardia (<50 bpm)
  • High-degree AV block without pacemaker
  • Decompensated heart failure
  • Severe reactive airway disease (relative contraindication)
  • Cocaine use

Side effects: Fatigue, erectile dysfunction, bradycardia, hypotension, bronchospasm

Calcium Channel Blockers (CCBs) [1,2]

Indications:

  • Beta-blocker intolerant or contraindicated
  • Persistent symptoms despite beta-blocker therapy
  • Vasospastic (Prinzmetal) angina (Class 1)

Non-Dihydropyridines (rate-limiting):

  • Diltiazem (extended-release): 120-360 mg once daily
  • Verapamil (extended-release): 120-480 mg once daily
  • Mechanism: ↓ heart rate, ↓ contractility
  • Caution: Do NOT combine with beta-blockers (risk of bradycardia, heart block)

Dihydropyridines (vasodilators):

  • Amlodipine: 2.5-10 mg once daily
  • Nifedipine (long-acting): 30-90 mg once daily
  • Mechanism: Peripheral vasodilation, ↓ afterload
  • Can be combined with beta-blockers
  • Side effects: Peripheral edema, flushing, headache
Ranolazine [1,2]

Mechanism: Late sodium current inhibitor; reduces intracellular calcium overload; improves diastolic function

Dose: 500 mg twice daily initially, titrate to 1000 mg twice daily

Indications:

  • Refractory angina despite optimal therapy with beta-blockers and/or CCBs (Class 2a)
  • Particularly useful in patients with low blood pressure or heart rate (no hemodynamic effects)

Advantages: No effect on heart rate or blood pressure

Side effects: Dizziness, constipation, nausea

Contraindications: Severe hepatic impairment, QT prolongation, concurrent use of strong CYP3A inhibitors

Drug interactions: Potent CYP3A4 substrate; adjust dose with moderate CYP3A inhibitors (diltiazem, verapamil)

Ivabradine [2]

Mechanism: Selective If channel blocker in SA node; reduces heart rate without affecting contractility

Dose: 2.5-7.5 mg twice daily

Indications:

  • Symptomatic angina with heart rate >70 bpm despite beta-blocker therapy or if beta-blocker intolerant (Class 2b)
  • Requires sinus rhythm

Advantages: Pure heart rate reduction without negative inotropy or vasodilation

Side effects: Bradycardia, visual symptoms (phosphenes – transient enhanced brightness)

Contraindications: Atrial fibrillation, sick sinus syndrome, heart rate <60 bpm

Medications That Reduce Cardiovascular Events and Mortality

Antiplatelet Therapy

Aspirin (Class 1) [2,6]

  • Dose: 81 mg once daily (75-100 mg daily)
  • Mechanism: Irreversible COX-1 inhibition → ↓ thromboxane A2 → ↓ platelet aggregation
  • Mortality benefit: 15-30% reduction in cardiovascular events
  • Duration: Indefinite (lifelong)
  • Contraindications: Active bleeding, severe thrombocytopenia, aspirin allergy

P2Y12 Inhibitors (Alternative to Aspirin) [2]

  • Clopidogrel 75 mg once daily: Use if aspirin intolerant or allergic
  • Ticagrelor 60 mg twice daily: May be considered in select high-risk patients (Class 2b)
  • NOT recommended: Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) in stable CAD without recent ACS or PCI (increases bleeding risk without proven benefit)
Lipid-Lowering Therapy

High-Intensity Statins (Class 1) [2,6,7]

  • Atorvastatin 40-80 mg once daily OR
  • Rosuvastatin 20-40 mg once daily

Goals: [5]

  • Primary goal: LDL-C reduction ≥50% from baseline
  • LDL-C target: <70 mg/dL (ideally <55 mg/dL in very high-risk patients per 2023 ESC guidelines)

Benefits:

  • 25-35% reduction in major adverse cardiovascular events (MACE)
  • Plaque stabilization
  • Anti-inflammatory effects

Side effects: Myalgias, elevated liver enzymes (rare), increased diabetes risk (small)

Monitoring: Lipid panel at 4-12 weeks after initiation, then every 3-12 months

Additional Lipid-Lowering Therapy (if LDL-C not at goal on maximally tolerated statin): [5]

  • Ezetimibe 10 mg once daily (Class 1): Further ↓ LDL-C by 15-20%
    • Add if LDL-C ≥70 mg/dL on maximally tolerated statin
  • PCSK9 Inhibitors (Class 1):
    • Evolocumab 140 mg subcutaneous every 2 weeks OR 420 mg subcutaneous monthly
    • Alirocumab 75-150 mg subcutaneous every 2 weeks
    • Indications: LDL-C ≥70 mg/dL despite maximally tolerated statin + ezetimibe OR statin intolerance
    • Benefits: ↓ LDL-C by 50-60%; ↓ cardiovascular events by 15%
  • Bempedoic acid 180 mg once daily (Class 2a):
    • For statin-intolerant patients or as add-on therapy
    • ↓ LDL-C by 15-25%
  • Icosapent ethyl (Vascepa) 2 g twice daily with meals (Class 2a):
    • For patients with triglycerides 135-499 mg/dL on statin therapy
    • ↓ cardiovascular events by 25% (REDUCE-IT trial)
ACE Inhibitors or ARBs (Class 1)[2,6]

Indications (strong):

  • All patients with chronic coronary disease AND:
    • Diabetes mellitus
    • Chronic kidney disease (CKD)
    • Hypertension
    • Left ventricular ejection fraction (LVEF) ≤40%
    • Prior myocardial infarction

May be considered: All patients with chronic coronary disease (Class 2b)

Preferred ACE Inhibitors:

  • Lisinopril: 5-40 mg once daily
  • Ramipril: 2.5-10 mg once daily
  • Enalapril: 5-20 mg twice daily

ARBs (if ACE inhibitor not tolerated due to cough or angioedema):

  • Losartan: 25-100 mg once daily
  • Valsartan: 40-160 mg twice daily
  • Candesartan: 4-32 mg once daily

Benefits: ↓ cardiovascular events, ↓ mortality (especially in high-risk patients), prevent LV remodeling

Monitoring: Check potassium and creatinine within 1-2 weeks of initiation

Contraindications: Pregnancy, bilateral renal artery stenosis, hyperkalemia, history of angioedema

Beta-Blockers (Class 1 in Select Patients) [2]

Strong indications:

  • Prior myocardial infarction (Class 1) – ↓ mortality, ↓ reinfarction
  • Heart failure with reduced ejection fraction (HFrEF) (Class 1)
  • Left ventricular systolic dysfunction (LVEF <40%)

May be considered: All patients with chronic coronary disease for symptom control (as above)

Mortality benefit: Well-established in post-MI and HFrEF populations

SGLT2 Inhibitors (Emerging – Class 2a) [2,8]

Indications:

  • Chronic coronary disease with type 2 diabetes mellitus OR heart failure

Preferred agents:

  • Empagliflozin: 10 mg once daily
  • Dapagliflozin: 10 mg once daily

Benefits: [8]

  • ↓ Heart failure hospitalizations by 30%
  • ↓ Cardiovascular death (in heart failure populations)
  • ↓ Progression of CKD
  • Improved glycemic control in diabetes

Monitoring: Risk of genital mycotic infections, volume depletion, euglycemic DKA (rare)

Contraindications: Type 1 diabetes, eGFR <20 mL/min/1.73m² (varies by agent)

GLP-1 Receptor Agonists (Class 2a in Select Patients) [2,6]

Indications:

  • Type 2 diabetes with atherosclerotic cardiovascular disease

Preferred agents with proven cardiovascular benefit:

  • Liraglutide: 1.2-1.8 mg subcutaneous once daily
  • Semaglutide: 0.5-1 mg subcutaneous once weekly OR 7-14 mg oral once daily
  • Dulaglutide: 1.5 mg subcutaneous once weekly

Benefits: ↓ MACE by 12-26% in patients with diabetes and established ASCVD

Side effects: Nausea, vomiting, diarrhea, pancreatitis (rare)

Colchicine (Class 2b) [2,9]

Dose: 0.5 mg once daily

Indication: May be considered for secondary prevention in chronic coronary disease (based on LoDoCo2 trial)

Benefits: ↓ Cardiovascular events by 31% (driven by ↓ revascularization, ↓ stroke)

No mortality benefit demonstrated

Side effects: Diarrhea, nausea

Contraindications: eGFR <30 mL/min, severe hepatic impairment

Blood Pressure Management [2,6]

Target: <130/80 mmHg (Class 1)

Preferred agents:

  • ACE inhibitors or ARBs (first-line)
  • Thiazide or thiazide-like diuretics (chlorthalidone, indapamide)
  • Calcium channel blockers (amlodipine, diltiazem, verapamil)
Diabetes Management[2,8]

HbA1c target: <7% (individualize based on patient factors)

Preferred glucose-lowering agents in CAD patients:

  1. SGLT2 inhibitors (empagliflozin, dapagliflozin) – Class 2a
  2. GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) – Class 2a

Avoid:

  • Thiazolidinediones (pioglitazone, rosiglitazone) – increase heart failure risk

Revascularization

Percutaneous Coronary Intervention (PCI) [1,2]

Indications (Class 1):

  • Refractory angina despite optimal medical therapy
  • High-risk features on non-invasive testing or angiography
  • Left main stenosis ≥50%
  • Proximal LAD stenosis ≥70%

Benefits:

  • Symptom relief superior to medical therapy alone
  • No mortality benefit in stable CAD (COURAGE, ISCHEMIA trials)

Stent preference: Drug-eluting stents (DES) over bare-metal stents (BMS)

Post-PCI antiplatelet therapy:

  • Aspirin 81 mg indefinitely (Class 1)
  • Clopidogrel 75 mg daily for 6 months (Class 1) – may extend to 12 months in high-risk patients
Coronary Artery Bypass Grafting (CABG) [1,2]

Indications (Class 1):

  • Left main disease ≥50% stenosis
  • Three-vessel disease with or without proximal LAD involvement (especially with diabetes or reduced LVEF)
  • Two-vessel disease with proximal LAD stenosis
  • Severe symptoms refractory to medical therapy with suitable anatomy

Benefits:

  • Mortality benefit over medical therapy alone in left main and multi-vessel disease
  • Superior to PCI in complex multi-vessel disease and diabetics

Post-CABG management:

  • Aspirin 81 mg indefinitely
  • High-intensity statin
  • Beta-blocker (if prior MI or reduced LVEF)
  • ACE inhibitor or ARB

Consults #

Cardiology
  • All patients with chronic coronary syndrome for risk stratification, stress testing, and consideration for angiography
  • Refractory symptoms despite optimal medical therapy
  • High-risk features on non-invasive testing
Cardiac Surgery
  • Left main disease or complex multi-vessel disease requiring CABG evaluation
  • Consideration for surgical revascularization
Cardiac Rehabilitation
  • All patients post-revascularization (PCI or CABG)
  • Patients with high-risk features or poor functional capacity
Dietitian
  • Medical nutrition therapy for cholesterol management, weight loss, diabetes control
  • Education on Mediterranean or DASH diet
Smoking Cessation Programs
  • All active smokers
Endocrinology
  • Uncontrolled diabetes (HbA1c >9%) despite primary care management
Psychiatry/Psychology
  • Depression screening (PHQ-9 ≥10)
  • Anxiety interfering with quality of life or medication adherence

Patient Education #

Counseling

Symptom Recognition and Management
  • Recognize anginal symptoms and differentiate from non-cardiac chest pain
  • Proper use of sublingual nitroglycerin:
    • Take at onset of chest pain or prophylactically before anticipated exertion
    • Sit or lie down (prevent falls from hypotension)
    • If pain persists after 3 doses over 15 minutes → call 911 (rule out ACS)
    • Store in original container, replace every 6 months
  • Avoid triggers: Heavy meals, cold exposure, emotional stress, overexertion
Medication Adherence
  • Emphasize lifelong therapy with aspirin, statins, and other medications
  • Discuss side effects and strategies to manage them
  • Address cost barriers and medication access
Lifestyle Modifications
  • Smoking cessation: Most important intervention
  • Regular exercise: Build up gradually; cardiac rehabilitation if appropriate
  • Heart-healthy diet: Mediterranean or DASH diet
  • Weight management: Achieve and maintain healthy BMI
  • Stress reduction: Mindfulness, meditation, counseling
Risk Factor Control
  • Monitor blood pressure at home (goal <130/80 mmHg)
  • Monitor blood glucose if diabetic (goal HbA1c <7%)
  • Limit alcohol consumption
Sexual Activity
  • Safe to resume if able to climb 2 flights of stairs without symptoms
  • Avoid PDE5 inhibitors (sildenafil, tadalafil, vardenafil) if on nitrates (risk of severe hypotension)
  • Use sublingual nitroglycerin prophylactically if needed before sexual activity
Depression Screening
  • Screen for depression (common in CAD patients)
  • Refer for treatment if PHQ-9 ≥10

Screening (USPSTF Recommendations)

Primary Prevention Screening (Not Applicable to Established CAD)

For patients WITHOUT established CAD, USPSTF recommends:

Aspirin for Primary Prevention[10]
  • Ages 40-59 with ≥10% 10-year CVD risk: Individualized decision (Grade C)
    • Small net benefit; consider bleeding risk
  • Ages ≥60: Do NOT initiate aspirin for primary prevention (Grade D)

Note: These recommendations do NOT apply to patients with established CAD. Patients with chronic coronary syndrome should be on aspirin 81 mg daily indefinitely for secondary prevention (Class 1).[2]

Statin for Primary Prevention[11]
  • Ages 40-75 with ≥1 CVD risk factor AND ≥10% 10-year CVD risk: Prescribe statin (Grade B)
  • Ages 40-75 with ≥1 CVD risk factor AND 7.5-10% 10-year CVD risk: Selectively offer statin (Grade C)

Note: Patients with established CAD should be on high-intensity statin therapy regardless of baseline LDL-C (Class 1).[2,7]

Vaccinations (Recommended for All CAD Patients)[2,6]

Influenza Vaccine (Class 1)
  • Annual vaccination recommended for all patients with cardiovascular disease
  • Reduces cardiovascular events and mortality
  • Administer in fall season (September-November)
Pneumococcal Vaccine (Class 1)
  • PCV20 (Prevnar 20): Single dose, OR
  • PCV15 (Prevnar 15) followed by PPSV23 (Pneumovax 23) ≥1 year later
  • Recommended for all adults ≥65 years and adults 19-64 years with cardiovascular disease
COVID-19 Vaccine (Class 1)
  • Stay up-to-date with current CDC recommendations
  • Reduces severe illness and cardiovascular complications
Tdap (Tetanus-Diphtheria-Pertussis)
  • One-time dose if not previously received
  • Td or Tdap booster every 10 years

Follow-Up #

Short-Term Follow-Up

Initial visit (2-4 weeks after diagnosis):

  • Assess response to anti-anginal medications
  • Review medication adherence and side effects
  • Reinforce lifestyle modifications
  • Evaluate need for stress testing or cardiology referral

Long-Term Follow-Up

Every 3-6 months initially, then annually if stable:

  • Reassess anginal symptoms (frequency, severity, pattern)
  • Monitor for progression (worsening symptoms, rest angina → suggests unstable angina)
  • Review medication adherence
  • Assess risk factor control:
    • Blood pressure (goal <130/80 mmHg)
    • Lipid panel (LDL-C <70 mg/dL, ideally <55 mg/dL)
    • HbA1c (goal <7% if diabetic)
    • Weight and BMI
  • Screen for depression (PHQ-9)
When to Repeat Stress Testing [2]

NOT routinely recommended in asymptomatic patients with stable disease

Consider repeat testing if:

  • Change in symptoms: New or worsening angina
  • Change in functional status: Decreased exercise tolerance
  • Before return to high-risk occupation (pilots, commercial drivers)
  • After revascularization if recurrent symptoms
When to Refer Back to Cardiology
  • Worsening or refractory angina despite optimal medical therapy
  • Change in anginal pattern (rest angina, crescendo angina)
  • Abnormal or high-risk features on repeat stress testing
  • Consideration for revascularization

References #

  1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425
  2. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. https://doi.org/10.1161/CIR.0000000000001168
  3. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. https://doi.org/10.1161/CIR.0000000000001052
  4. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. https://doi.org/10.1161/CIR.0000000000001123
  5. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368-e454. https://doi.org/10.1161/CIR.0000000000001029
  6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. https://doi.org/10.1161/CIR.0000000000000678
  7. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  8. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192
  9. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. https://doi.org/10.1056/NEJMoa2021372
  10. US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577-1584. https://doi.org/10.1001/jama.2022.4983
  11. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. https://doi.org/10.1001/jama.2022.13044

#

Updated on December 10, 2025